Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease

About this update from Oncodesign Precision Medicine S.a.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":320,"url":"https://media.zenfs.com/en/business-wire.com/09fcd30bedbbbc58d161c1c1a8e055e9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1DX61yN5tnOnIJLtLz9fGw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/09fcd30bedbbbc58d161c1c1a8e055e9","width":480,"height":320}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson’s disease and the execution of long-term toxicology study including study product preparation","length":216,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":216,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program and evaluation of OPM-201 within LITE’s standardized testing pipelines","length":177,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":177,"olType":false},{"type":"text","content":"DIJON, France, March 03, 2026--(BUSINESS WIRE)--Regulatory News:","length":64,"tagName":"p"},{"type":"text","content":"Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of advanced cancers, today announces it has been awarded US $6.92 M (about €5.84 M) grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) Therapeutic Pipeline Program (TPP). The grant aims to prepare OPM’s OPM-201 LRRK2 inhibitor to start its Phase 1b clinical study in 2027 in early people with Parkinson’s disease, with a focus on LRRK2 mutation carriers.","length":532,"tagName":"p"},{"type":"text","content":"This next step in OPM-201’s development follows the reacquisition of all rights to the program from its collaboration partner Servier in December 2024. OPM partners with expert collaborators on opportunities and assets delivered by its innovative technologies outside of oncology. These partnerships have enabled OPM to reach the current stage of clinical development for its asset OPM-201.","length":390,"tagName":"p"},{"type":...

More updates from Oncodesign Precision Medicine S.a.